Adverum Biotechnologies Performance
| ADVMDelisted Stock | USD 4.36 0.00 0.00% |
Adverum Biotechnologies has a performance score of 8 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -1.04, which signifies a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Adverum Biotechnologies are expected to decrease slowly. On the other hand, during market turmoil, Adverum Biotechnologies is expected to outperform it slightly. Adverum Biotechnologies right now shows a risk of 1.05%. Please confirm Adverum Biotechnologies value at risk, as well as the relationship between the skewness and relative strength index , to decide if Adverum Biotechnologies will be following its price patterns.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Adverum Biotechnologies are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Adverum Biotechnologies may actually be approaching a critical reversion point that can send shares even higher in February 2026. ...more
| Begin Period Cash Flow | 77 M | |
| Total Cashflows From Investing Activities | -41.9 M |
Adverum |
Adverum Biotechnologies Relative Risk vs. Return Landscape
If you would invest 423.00 in Adverum Biotechnologies on October 29, 2025 and sell it today you would earn a total of 13.00 from holding Adverum Biotechnologies or generate 3.07% return on investment over 90 days. Adverum Biotechnologies is currently generating 0.1062% in daily expected returns and assumes 1.047% risk (volatility on return distribution) over the 90 days horizon. In different words, 9% of stocks are less volatile than Adverum, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Adverum Biotechnologies Target Price Odds to finish over Current Price
The tendency of Adverum Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 4.36 | 90 days | 4.36 | about 39.06 |
Based on a normal probability distribution, the odds of Adverum Biotechnologies to move above the current price in 90 days from now is about 39.06 (This Adverum Biotechnologies probability density function shows the probability of Adverum Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Adverum Biotechnologies has a beta of -1.04. This suggests Additionally Adverum Biotechnologies has an alpha of 0.5283, implying that it can generate a 0.53 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Adverum Biotechnologies Price Density |
| Price |
Predictive Modules for Adverum Biotechnologies
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Adverum Biotechnologies. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Adverum Biotechnologies' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Adverum Biotechnologies Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Adverum Biotechnologies is not an exception. The market had few large corrections towards the Adverum Biotechnologies' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Adverum Biotechnologies, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Adverum Biotechnologies within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.53 | |
β | Beta against Dow Jones | -1.04 | |
σ | Overall volatility | 0.54 | |
Ir | Information ratio | 0.07 |
Adverum Biotechnologies Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Adverum Biotechnologies for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Adverum Biotechnologies can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Adverum Biotechnologies is not yet fully synchronised with the market data | |
| Adverum Biotechnologies has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1000 K. Net Loss for the year was (130.93 M) with loss before overhead, payroll, taxes, and interest of (77.12 M). | |
| Adverum Biotechnologies currently holds about 235.84 M in cash with (92.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.37. | |
| Over 88.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 10200 shares by Smith J. Jefferson of Precision BioSciences at 4.03 subject to Rule 16b-3 |
Adverum Biotechnologies Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Adverum Stock often depends not only on the future outlook of the current and potential Adverum Biotechnologies' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Adverum Biotechnologies' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 19.8 M | |
| Cash And Short Term Investments | 125.7 M |
Adverum Biotechnologies Fundamentals Growth
Adverum Stock prices reflect investors' perceptions of the future prospects and financial health of Adverum Biotechnologies, and Adverum Biotechnologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Adverum Stock performance.
| Return On Equity | -4.18 | |||
| Return On Asset | -0.77 | |||
| Current Valuation | 159.14 M | |||
| Shares Outstanding | 22.08 M | |||
| Price To Earning | (2.10) X | |||
| Price To Book | 0.93 X | |||
| Price To Sales | 94.37 X | |||
| Revenue | 1000 K | |||
| EBITDA | (135.51 M) | |||
| Cash And Equivalents | 235.84 M | |||
| Cash Per Share | 2.37 X | |||
| Total Debt | 91.7 M | |||
| Debt To Equity | 0.43 % | |||
| Book Value Per Share | (2.53) X | |||
| Cash Flow From Operations | (92.46 M) | |||
| Earnings Per Share | (8.57) X | |||
| Total Asset | 179.84 M | |||
| Retained Earnings | (1.07 B) | |||
| Current Asset | 260.99 M | |||
| Current Liabilities | 6.57 M | |||
About Adverum Biotechnologies Performance
By examining Adverum Biotechnologies' fundamental ratios, stakeholders can obtain critical insights into Adverum Biotechnologies' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Adverum Biotechnologies is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California. Adverum Biotechnlgs operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 188 people.Things to note about Adverum Biotechnologies performance evaluation
Checking the ongoing alerts about Adverum Biotechnologies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Adverum Biotechnologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Adverum Biotechnologies is not yet fully synchronised with the market data | |
| Adverum Biotechnologies has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1000 K. Net Loss for the year was (130.93 M) with loss before overhead, payroll, taxes, and interest of (77.12 M). | |
| Adverum Biotechnologies currently holds about 235.84 M in cash with (92.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.37. | |
| Over 88.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 10200 shares by Smith J. Jefferson of Precision BioSciences at 4.03 subject to Rule 16b-3 |
- Analyzing Adverum Biotechnologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Adverum Biotechnologies' stock is overvalued or undervalued compared to its peers.
- Examining Adverum Biotechnologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Adverum Biotechnologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Adverum Biotechnologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Adverum Biotechnologies' stock. These opinions can provide insight into Adverum Biotechnologies' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in Adverum Stock
If you are still planning to invest in Adverum Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Adverum Biotechnologies' history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |